An observational study in Tetralogy of Fallot (TOF) and Congenital Heart Defects, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Tetralogy of Fallot is the most common cyanotic congenital heart disease. Management strategies vary between primary repair and staged approaches including palliative surgery. The development of pulmonary arteries is a key determinant in surgical decision-making.
This multicenter retrospective observational study aims to evaluate the evolution of pulmonary artery dimensions using the Nakata index at key stages of patient management (birth, palliative surgery, and complete repair). The goal is to assess its predictive value in optimizing surgical strategy and improving outcomes in patients with Tetralogy of Fallot or pulmonary atresia with ventricular septal defect.
92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.
This study's planned enrollment of 400 is above the median of 150 across 40 observational studies indexed under Tetralogy of Fallot.
Browse Tetralogy of Fallot studies →University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pediatric patients with Tetralogy of Fallot or related conditions managed surgically in tertiary care centers in Strasbourg and Bordeaux.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nakata index evolution and predictive value
Assessment of the Nakata index based on pulmonary artery diameters measured on imaging at different time points (birth, palliative surgery, complete repair), and evaluation of its association with surgical outcomes using predefined thresholds (108 and 160 mm²/m²).
Time frame: From birth to complete surgical repair (retrospective data 2010-2024)
Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →